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SUMMARY
This randomized, noninferiority trial included patients aged 1-14 years who presented to the emergency department (ED) with acute asthma. Primary objective was to compare the efficacy of two doses of dexamethasone (0.6 mg/kg/dose, experimental treatment) and a 5-day course of prednisolone/prednisone (1.5 mg/ kg/d, followed by 1 mg/kg/d on days 2-5, conventional treatment). The primary outcome measures were the percentage of patients with asthma symptoms and quality of life at day 7. Secondary outcomes were unscheduled returns, admissions, adherence, and vomiting.
During the study period, 710 children who met the inclusion criteria were invited to participate and 590 agreed. Primary outcome data were available in 557 patients. At day 7, experimental and conventional groups did not show differences related to persistence of symptoms (56.6%, 95% CI 50.6 to 62.6 vs 58.3%, 95% CI 52.3 to 64.2, respectively), quality of life score (80.0 vs 77.7), admission rate (23.9% vs 21.7%), unscheduled ED return visits (4.6% vs 3.3%), and vomiting (2.1% vs 4.4%). Adherence was greater in the dexamethasone group (99.3% vs 96.0%, P<0.05). Authors concluded that two doses of dexamethasone may be an effective alternative to a 5-day course of prednisone/prednisolone for asthma exacerbations, as measured by persistence of symptoms and quality of life at day 7.
COMMENTARIES
Evidence-based Medicine Viewpoint
Relevance: Administration of parenteral corticosteroids is a standard of care for acute asthma exacerbations in children and adults. This is reflected in most evidencebased guidelines, irrespective of whether initial management is started at home, primary health-care facilities or hospitals [1] [2] [3] [4] . In fact, these guidelines recommend initiation of steroid therapy within the first hour of management in all except mild exacerbations. Oral administration has been shown to be as effective as intravenous or intramuscular administration. Thus, oral prednisone/prednisolone in the dose of 1-2 mg/kg per day has been recommended for a total of 5-7 days; although some studies have examined shorter courses and/or lower doses.
A limited number of studies also compared prednisone versus dexamethasone with the goal of evaluating whether the duration of therapy and/or number of doses could be reduced. There are four reasonably well-designed trials comparing oral prednisone versus oral dexamethasone in children [5] [6] [7] [8] . A relatively recent Cochrane systematic review [9] reported that both medications had comparable efficacy in terms of hospital admission frequency (OR 1.08; 95% CI 0.74, 1.58; 3 trials; 1007 participants), re-admission to hospital (OR 0.44; 95% CI 0.15, 1.33; 3 trials; 985 participants), new exacerbations during the follow-up period necessitating unplanned visits to health-care providers (OR 0.85; 95% CI 0.54, 1.34; 4 trials; 981 participants), new exacerbations requiring additional oral steroids (OR 0.29. 95% CI 0.10, 0.81; 1 trial; 242 participants), and prevalence of vomiting (OR 3.05; CI 0.88, 10.55; 3 trials; 867 participants). Two of the four trials in the review reported comparable symptom scores between the two groups. Overall, these data suggest that dexamethasone has comparable (but not superior) efficacy and safety to prednisone. However, the trials had differences in terms of dose and/or duration of medications, outcomes studied, timing of outcome assessment, and methodological quality. Table I summarizes the characteristics of the trials and their differences.
One more trial comparing prednisone and dexamethasone has been recently published [10] . The trial characteristics are compared to the previous trials in VOLUME 55 __ 
= 28%).
Critical appraisal: Methodological critical appraisal using the Cochrane Risk of Bias tool [11] is presented in Table II .
The trial included several methodological refinements. It was designed as a non-inferiority trial necessitating a larger sample size. In fact, this is the only non-inferiority trial comparing dexamethasone versus prednisone. The trial included fairly robust definitions/ criteria for asthma, exacerbations, and the scores used to calculate symptom persistence and quality of life. Although most outcomes were based on parental report, some of the data were retrieved from electronic records reducing the risk of bias in parental reporting.
However, there are some significant limitations worth mentioning. The investigators chose two patient-centric measures (viz symptom persistence and QoL score on day 7) as the primary outcomes rather than the conventional objective measures of improvement (such as symptom scores, need for admission, step-up of therapy/care, etc). The authors attempted to justify this decision, but the arguments are weak. Since three of the four previous trials were already available when this trial was started, it would have been better to align the outcomes to facilitate comparison with existing data. Further, both the primary outcomes were based on parental report, and that too, obtained over telephone, rather than a face-to-face interview. This makes it difficult to assess the reliability of these outcome measures.
Despite this, the investigators did not choose to ensure blinding of the parents/children and personnel collecting data over the phone. In a trial of this nature, this would have been relatively easy using the double-dummy design. The impact of absence of blinding of these groups is difficult to assess in this trial.
One of the major challenges in this trial is a very high proportion of children with persistence of symptoms at the end-point (7 days). In fact, 57% children who received dexamethasone and 58% of those receiving prednisone continued to be symptomatic well after therapy was discontinued. This suggests a high rate of treatment failure (even though it was comparable between the two groups). No clear explanation was offered by the authors for this; although the doses and durations in both groups The participants in both groups were comparable in terms of age, gender distribution, characteristics of the exacerbation, and symptom persistence.
Randomization
Adequate; A computer program was used to generate the allocation sequence.
Allocation concealment Adequate; The allocation of individual children was concealed in serially numbered opaque envelopes.
Blinding of participants and personnel Inadequate; This was not done.
Blinding of outcome assessors Inadequate; This was not done.
Incomplete outcome data Unclear; The trial randomized 590 children, but despite planning an intention-to-treat analysis, results were reported only in 557. The proportion of children whose data were missing was 4.4% in dexamethasone group and 6.8% in prednisone group.
Selective outcome reporting Adequate; All the outcomes planned, were measured and reported. Further careful analysis of the primary outcome measures shows that the proportion of children with symptom persistence (in both groups) was higher at the end-point than at the baseline (56.6% compared to 43.8% for dexamethasone; and 58.3% compared to 37.7% for prednisone). This seems strange, but no explanation has been offered. In fact, each of the components of the symptom persistence scoring system also showed worsening after therapy (than at baseline) in both groups. Further, the QoL score remained unchanged after therapy (80.0 vs 79.4 for dexamethasone; and 77.7 vs 79.5 for prednisone). This is also difficult to explain. It is possible that these apparently unusual observations could be related to data being obtained by direct interview at baseline, but by telephone at the end-point. This again highlights that the primary outcome measures in this study were not ideal.
In contrast, most of the secondary outcome measures did not suggest that the apparent treatment failure necessitated medical attention to the same extent. For example, there was very low hospitalization rate, hospital re-admission rate, unscheduled visits to healthcare provider(s), need for additional steroids, and school absenteeism. However, one outcome designated 'admission to observation unit' was present in nearly one-fifth of all children. Unfortunately, the details have not been described, but it could suggest need for further care in a significant proportion of the children (although the rate was comparable between the groups). These observations suggest that dexamethasone and prednisone had a very high (through comparable) lack of efficacy in this trial. The only outcome tilted in favor of dexamethasone was lack of adherence; although, it was extremely low in both groups. However, as this was also based purely on parental report, the veracity is questionable.
The investigators suggested very high parental satisfaction at the end-point; however, this outcome does not appear to have been measured in all the children. Strangely, parental satisfaction is reported in 99.3% and 96.0% in the dexamethasone and prednisone groups, respectively, whereas the respective absolute numbers are only 210 and 179. This makes it difficult to interpret this outcome.
Last but not the least, the investigators planned intention-to-treat analysis. In its purest sense this implies that all randomized participants should appear in the analysis, and not only those for whom data are available, or those who complete the trial per protocol [12] . In this trial, 590 children were randomized (and should have constituted the denominator), whereas data were analyzed using only 557 children.
Extendibility: Both medications used in this trial are easily available in our setting in various formulations and packaging, making it easy to administer. Further, the possibility of reducing treatment duration from 5 days to 2 days (by using dexamethasone instead of prednisone) makes it an attractive proposition. However, the data from this trial do not provide compelling evidence to switch from the current standard of care to an alternative strategy. This is because there are several concerns with the internal validity of the trial (highlighted above). Further, the four previous trials also demonstrated only comparability, but not superiority of dexamethasone over prednisone.
Conclusion:
This randomized trial showed that the treatment of acute asthma (except severe cases) with oral dexamethasone had comparable efficacy to oral prednisone, although a high rate of treatment failure was observed in both groups. Updated meta-analysis confirmed comparable efficacy outcomes, but vomiting was significantly lower with dexamethasone. This is a new finding not identified in the previous meta-analyses [9] .
